Skip to main content
. 2004 Jan 31;53(3):187–195. doi: 10.1007/s00262-003-0480-x

Fig. 1.

Fig. 1

A strategy for identification, selection, and validation of tumor-associated HLA peptides for cancer immunotherapy. The approach can be used for patient-individualized treatments as well as to compose sets of “universal” tumor-associated peptides